Article
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.
Nature - 1 Jul 2023
Kim Dongsung, Herdeis Lorenz, Rudolph Dorothea, Zhao Yulei, Böttcher Jark, Vides Alberto, Ayala-Santos Carlos I, Pourfarjam Yasin, Cuevas-Navarro Antonio, Xue Jenny Y, Mantoulidis Andreas, Bröker Joachim, Wunberg Tobias, Schaaf Otmar, Popow Johannes, Wolkerstorfer Bernhard, Kropatsch Katrin Gabriele, Qu Rui, de Stanchina Elisa, Sang Ben, Li Chuanchuan, McConnell Darryl B, Kraut Norbert, Lito Piro
Abstract excerpt
KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C in its inactive conformation and suppress tumour growth in patients1-7. Whether inactive-state selective inhibition can be used to therapeutically target non-G12C...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.